20 results on '"Alsina, Melissa"'
Search Results
2. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma
3. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma
4. A Comparison of Salvage Infusional Chemotherapy Regimens for Recurrent/Refractory Multiple Myeloma
5. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
6. Immunotherapy strategies for multiple myeloma: the present and the future
7. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
8. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma
9. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
10. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study
11. Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications
12. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
13. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
14. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma
15. Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib
16. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: Final time-to-event results from the SUMMIT trial
17. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
18. Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity
19. A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
20. Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.